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Cyclostreptin, a natural product from Streptomyces sp.9885, irreversibly 
stabilizes cellular microtubules, causes cell cycle arrest, evades P-glycoprotein-
mediated drug resistance of a tumor cell line, potently inhibits paclitaxel binding to 
microtubules, yet only weakly induces tubulin assembly. In trying to understand this 
paradox, we observed irreversible binding of synthetic cyclostreptin to tubulin. This 
results from formation of covalent crosslinks to β-tubulin in cellular microtubules and 
microtubules formed from purified tubulin in 1:1 total stoichiometry distributed 
between Thr220 (at the outer surface of a pore in the microtubule wall) and Asn228 
(at the lumenal paclitaxel site). Unpolymerized tubulin was only labeled at Thr220. 
Thus, the pore region of β-tubulin is an undescribed binding site that elucidates the 
mechanism by which taxoid site compounds reach the kinetically unfavorable 
lumenal site and explains how taxoid site drugs induce microtubule formation from 




The mitotic spindle is an important target in cancer chemotherapy1. Spindle 
function is dependent on microtubule dynamics, which involves stochastic gain and 
loss of αβ-tubulin heterodimers from microtubule ends. Growth or shortening 
depends on the activation state of tubulin, controlled by the exchangeable nucleotide 
bound to the β-subunit. "Activated" tubulin-GTP adds to microtubule ends, while 
"deactivated" tubulin-GDP dissociates from polymer ends and will not normally 
polymerize into microtubules. 
Compounds that bind to tubulin arrest cells in mitosis and cause apoptosis. At 
intracellular concentrations far below the tubulin concentration, these agents interfere 
with microtubule dynamics2. Inhibitors of assembly, such as colchicine, inactivate 
tubulin, preventing microtubule formation. In contrast, microtubule stabilizing agents 
(MSAs), such as paclitaxel, bind preferentially to assembled tubulin, minimizing 
dissociation of tubulin-GDP from microtubule ends3. MSAs also induce assembly of 
the otherwise inactive tubulin-GDP4. In recent years, many structurally diverse taxoid 
site MSAs were discovered, including epothilone B and discodermolide, 
biochemically more potent than paclitaxel5, and cyclostreptin (FR182877) (Fig. 1a), 
which, while apparently less active than paclitaxel, has unusual biochemical 
properties6. 
Paclitaxel-stabilized, zinc-induced sheets of antiparallel tubulin protofilaments 
were used for construction of a model of tubulin with bound paclitaxel7, and, after 
fitting this model into electron density microtubule maps, it was concluded that 
paclitaxel binds to β-tubulin facing the microtubule lumen8. This model is supported 
by tubulin mutation data from cells resistant to paclitaxel and epothilones9. 
Two points remain obscure in the biochemical mechanism by which taxoid site 
ligands induce tubulin assembly. First, examination of the binding kinetics of 
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paclitaxel10 yields a high kf (3.6×106 M-1s-1) inconsistent with a relatively inaccessible 
lumenal binding site. An exposed site is also supported by reduction in the paclitaxel 
binding rate caused by microtubule-associated proteins (MAPs)10 and by 
antifluorescein antibody binding to a fluorescein labeled taxoid bound to 
microtubules11. These findings led us to propose an initial binding site for paclitaxel 
on the outer microtubule wall near pore type I, which is close to the lumenal site, 
followed by translocation of the drug to its lumenal site10. Since there is 1:1 
stoichiometry for paclitaxel binding to αβ-tubulin, the two sites must be mutually 
exclusive, perhaps with a shared element. 
Second while apparently the paclitaxel site exists only in assembled 
microtubules12, taxoid site drugs can induce microtubule assembly under conditions 
in which tubulin is normally unable to assemble and thus no binding sites can be 
demonstrated. Therefore, since assembly occurs, we postulated a low affinity binding 
site in tubulin dimers or oligomers, whose existence could not be demonstrated due 
to low paclitaxel solubility12. 
Although cyclostreptin13 weakly stimulates tubulin assembly, it avidly binds to 
microtubules, strongly inhibiting the binding of other MSAs to polymer. In addition, 
cyclostreptin-stabilized microtubules disassemble at 0 °C more slowly than paclitaxel-
stabilized microtubules6. We have now found that cyclostreptin interacts covalently 
both in vitro and in cells with polymerized tubulin, blocking the binding of even the 
most potent taxoid site ligands. Moreover, cyclostreptin is fully active in multidrug 
resistant (MDR) A2780/AD cells overexpressing P-glycoprotein (P-gp), indicating that 
covalent binding might be a way to overcome MDR. With HPLC-MS, we found that 
two amino acid residues, Thr220 and Asn228a, were modified in polymerized β-
tubulin (Asn228 is near the taxoid site facing the microtubule lumen, Thr220 abuts 
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Cyclostreptin binds irreversibly to microtubules and blocks binding of taxoid 
site ligands. Since cyclostreptin strongly inhibits binding of taxoid site ligands to 
microtubules, we tried to detect microtubule-bound cyclostreptin. Cyclostreptin-
treated microtubules were analyzed by HPLC-MS. Controls showed that cyclostreptin 
should have been detectable, but the pellet extracts were devoid of the compound 
(Fig. 1b, black lines). Ligand in the supernatant (red lines) was greatly reduced 
following incubation of cyclostreptin with microtubules. In the absence of degradation 
products, cyclostreptin must have reacted irreversibly with the protein. 
We examined competition among taxoid site ligands of different affinities for 
microtubules (discodermolide, epothilone B, epothilone A, cyclostreptin, and 
paclitaxel; Kd's at 35 °C of 0.18, 1.3, 28, 49 and 70 nM, respectively)5,6,14. The 
competition experiments were performed by adding labeled competitor before or after 
unlabeled ligand (Table I). All ligands except cyclostreptin behaved as expected if 
binding reversibly to the same site (order of ligand addition had no effect). With 
cyclostreptin, the feeble inhibition of discodermolide and epothilone B binding and 
strong inhibition of paclitaxel binding without a preincubation became near total 
inhibition with a preincubation. We also examined the binding to microtubules of 7-O-
[N-(2,7-difluoro-4'-fluoresceincarbonyl)-L-alanyl]paclitaxel (Flutax-2) a fluorescent 
analog of paclitaxel15, which bound with an apparent Kd of 14 nM, but not to 
microtubules preincubated with cyclostreptin (Fig. 1c). 
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Cyclostreptin and docetaxel displace Flutax-2 by different mechanisms. 
Cyclostreptin can displace Flutax-2 from stabilized microtubules with an apparent Ka 
similar to those of paclitaxel and docetaxel6. To determine whether the same 
mechanism was involved15, we compared the effects of docetaxel and cyclostreptin 
on the kinetics of Flutax-2 dissociation (Fig. 1d). 
 Docetaxel displaces Flutax-2 from microtubules because kf•[docetaxel] >> 
Flutax-2 dissociation rate constant kr15. With any excess [docetaxel], every empty site 
is rapidly filled by docetaxel (Fig. 1d, Left Inset). The Flutax-2 kr determined here was 
8.9 ± 0.3×10-3 s-1 at 2 and 20 µM docetaxel (cf.15). 
 Cyclostreptin was very different. Although 2-40 µM cyclostreptin fully displaced 
bound Flutax-2 following monoexponential kinetic curves (Fig. 1d), the observed 
dissociation rate constant (kobs) increased with [cyclostreptin] until it equaled the kr of 
Flutax-2 obtained with docetaxel (Fig. 1d, Right Inset). This indicates that the overall 
reaction is limited by the rate of cyclostreptin binding to microtubules. The 
explanation that cyclostreptin binds relatively slowly, with rebinding of free Flutax-2, 
is inconsistent with the monoexponential kinetic curves. These indicate a constant 
reaction rate, while increasing [Flutax-2] should cause the apparent kr to decrease 
over time. 
 An alternative explanation is that cyclostreptin binds to the Flutax-2-




where T represents the taxoid site in microtubules, C is cyclostreptin, and F is Flutax-
2. Then the observed reaction step would be the second, with monophasic kinetics at 
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steady state ([TCF] constant during the experiment), with the rate dependent on 
[cyclostreptin]. Curve fitting16 to this kinetic model yielded a k+2 value of 0.008±0.002 
s-1, in agreement with the 0.006 s-1 value for Flutax-2 dissociation at 25 °C with 
docetaxel15, a negligible k-1 value and a k+1 value of 350±20 M-1s-1. These values 
indicate an irreversible reaction has occurred. 
 
Cellular effects of cyclostreptin. Competition experiments of cyclostreptin with 
Flutax-2 were performed with unfixed cytoskeletons from PtK2 cells. When 
cyclostreptin or paclitaxel was added to cytoskeletons with bound Flutax-2, both 
compounds displaced Flutax-2. PtK2 cytoskeletons preincubated with paclitaxel, but 
not those preincubated with cyclostreptin, bind Flutax-2 (Fig. 2a-c), showing 
irreversible binding of cyclostreptin to the cytoskeletons.  
Similarly, there were differences in the effects of cyclostreptin and paclitaxel 
on cellular microtubules. There was partial recovery of the microtubule network in 
paclitaxel-treated PtK2 cells, but the effects of cyclostreptin were irreversible. Cells 
were incubated 7 h with 2 or 5 µM cyclostreptin or 10 µM paclitaxel, extensively 
washed and incubated 16 or 48 h longer. Untreated cells had typical microtubule 
networks after 7 or 23 h (Fig. 2d,g) and normal nuclei. Cells incubated 7 h with ligand 
had microtubule bundles (Fig. 2e,f) a small percentage of them were micronucleated 
(4% of the cells) or arrested in mitosis with multiple asters. 
After washing and another 16 h in culture, the cyclostreptin effect progressed: 
the bundles were unchanged (Fig. 2h), and cells with micronucleation or multipolar 
spindles increased in number to about 70%. With paclitaxel, microtubules reverted to 
a normal appearance (Fig. 2i), although the number of micronucleated cells had 
increased to about 70%. After a 48 h recovery, cyclostreptin-treated cells had 
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somewhat sparser microtubule bundles but an unchanged number of micronucleated 
cells. After 48 h without drug, paclitaxel-treated cells continued to recover, with 
micronucleation reduced to about 40%. 
         The PtK2 cells were examined for DNA content by flow cytometry 
(Supplementary Table 1), and these data also indicated a larger recovery following 
paclitaxel versus cyclostreptin treatment, with a larger population of G2+M cells 
persisting following cyclostreptin treatment.  
We tested the cytotoxicity of cyclostreptin in paclitaxel-resistant and non-
resistant carcinoma cell lines (Table 2). Cyclostreptin was around 40 times less 
active than paclitaxel in non-resistant lines, while the relative resistance observed in 
PTX10 and PTX22 was reduced from 27 and 17 for paclitaxel to 5 and 1.3 for 
cyclostreptin. In the MDR line, however, cyclostreptin was highly active, with a 
resistance factor of 1.2, as compared with 600-900 for paclitaxel and docetaxel. 
Cell cycle analysis was performed in PtK2, A549, A2780 and A2780/AD cells 
incubated for 24 h with paclitaxel or cyclostreptin. The lowest concentrations that 
gave maximal accumulation of cells in the G2+M phase were 0.5 µM, 20 nM, 15 nM, 
and 1 µM, respectively, for paclitaxel, while for cyclostreptin this concentration was 
100 nM in the four cell lines. Thus, cyclostreptin was more active than paclitaxel in 
the cell lines least sensitive to paclitaxel (PtK2 and A2780/AD) (Supplementary 
Table 2). 
 
 Characterization of cyclostreptin binding site by MS.  MS chromatograms of 
digested tubulin samples, derived from untreated (Fig. 3a) or cyclostreptin-treated 
(Fig. 3b top) microtubules showed differential, intense peaks corresponding to 
tubulin peptides producing a cyclostreptin-derived fragment ion at m/z 249.0 (see 
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Materials and Methods; Peaks 1-2 and 3-7 in the trypsin- and chymotrypsin-digested 
samples, respectively). These signals were absent in control samples (Fig. 3a, black 
arrows). MS/MS-based peptide sequencing (Supplementary Fig. 1) of Peaks 1 to 7 
demonstrated that all peptide sequences map into residues 219-243 of β-tubulin (Fig. 
3c). This sequence contains part of the taxoid site7. Peaks 1 and 2 correspond, 
respectively, to oxidized and non-oxidized, cyclostreptin-modified 
LTTPTYGDLNHLVSATMSGVTTCLR. The cyclostreptin-tagged peptide appeared in 
triply and quadruply charged form in the analyzed mass range. Peaks 3 to 7 
correspond to the sequences indicated (Fig. 3c). A comprehensive study of the 
fragmentation spectrum from the parent ion corresponding to Peak 2 revealed the 
peptide spanning residues 219-243 as the binding site for cyclostreptin 
(Supplementary Fig. 1a), but the > 3 kDa size of this peptide made the precise 
modification site uncertain. Analysis of the fragmentation spectrum from the peptides 
spanning residues 220-230 (Peak 5) (Supplementary Fig. 1b) and 220-235 (Peak 7) 
revealed that Thr220 formed a covalent bond with cyclostreptin. Analysis of the 
fragmentation spectra from the ions corresponding to Peaks 3, 4 and 6 
(Supplementary Fig. 1c) demonstrated a second modification site, Asn228. No 
doubly-labeled peptides were found, so the covalent reactions with Thr220 and 
Asn228 are mutually exclusive. Although relative areas measured from 
chromatographic peaks corresponding to chymotryptic peptides from cyclostreptin-
treated samples (Fig. 3b, right) indicate a more extensive reaction with asparagine 
versus threonine, ionization of chromatographically separated peptides is significantly 
influenced by the composition of the pool of accompanying peptides eluted at a given 
retention time. The relative reactivity of the two amino acid residues thus cannot be 
determined reliably by MS analysis. 
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However, the chromatographic signal corresponding to 
LTTPTYGDLNHLVSATMSGVTTCLR showed that there is a 1:1 stoichiometry for the 
interaction of cyclostreptin with αβ-tubulin in microtubules (Supplementary Fig. 2). 
In the extracted ion chomatography (EIC) for triply-charged ions, this peptide was 
present in one of two alternative forms. Without cyclostreptin, unmodified 
LTTPTYGDLNHLVSATMSGVTTCLR (m/z 884.4 Da) was observed. When 
cyclostreptin was included in the reaction mixture, only the corresponding peptide 
with one cyclostreptin added (m/z 1017.6 Da) was observed. Thus, all β-tubulin 
subunits in the microtubules were modified by addition of a single cyclostreptin. 
Similar experiments were performed under nonpolymerizing reaction 
conditions, where either the heterodimer or small oligomeric species predominate, 
depending on the Mg2+ concentration. Analysis of precursor ion scanning 
experiments demonstrated the presence of weak chromatographic Peaks 1, 2 and 5, 
but not Peaks 3, 4, 6 and 7. Thus, only formation of small amounts of the Thr220 
adduct in nonpolymerized tubulin was detectable (from peak intensity, less than 5% 
with oligomeric tubulin and less than 0.5% with heterodimeric tubulin). To verify these 
results and gain sensitivity, samples were also analyzed by multiple reaction 
monitoring (MRM) scan mode, fixing the Q3 quadrupole for the detection of the 
diagnostic ion at m/z 249.0 Da. Ions at m/z 1017.6, 636.8, 816.4, and 779.4 (at the 
m/z of chromatographic Peaks 2, 4, 5, and 6) were isolated and fragmented. Only 
precursors and fragmentation spectra from ions corresponding to Peaks 2 and 5 
were detected (Fig. 3b bottom), again unambiguously documenting the Thr220 
modification. No evidence was found for ions corresponding to Peaks 4 and 6, which 
contain the modified Asn228. The MRM experiments confirmed that the modified 
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peaks were 10-fold more intense in peptides derived from oligomeric versus dimeric 
tubulin samples. 
To be sure the Thr220 modification found in microtubules had not occurred in 
oligomers prior to microtubule assembly, microtubules stabilized by paclitaxel at a 
concentration (22 µM paclitaxel, 20 µM tubulin) much greater than the 1 µM drug 
required to supress microtubule dynamics17 were incubated with excess 
cyclostreptin. This results in cyclostreptin displacing paclitaxel from the preformed 
microtubules. Since paclitaxel binding to microtubules is reversible, cyclostreptin 
should bind to transiently unoccupied sites, progressively displacing the bound 
paclitaxel. Therefore the very same labeling would be expected, unless the Thr220 
modification occurred in oligomers prior to microtubule assembly, in which case only 
labeling at Asn228 should be observed. In MRM experiments, ions at m/z 1017.6, 
636.8, 816.4, and 779.4 (Peaks 2, 4, 5 and 6) were detected, while in precursor ion 
scanning experiments, using the ion at m/z 249.0 as the diagnostic signal, we also 
found tubulin-derived peptides corresponding to Peaks 3 and 7. Thus, the 
modifications at Thr220 and Asn228 were unambiguously documented again. We 
therefore conclude that the Thr220 modification must occur during the binding of 
cyclostreptin to microtubules. 
 
Cyclostreptin-labeling of cellular tubulin. To verify that the tubulin-cyclostreptin 
adduct is formed in treated cells, A549 cells were incubated 24 h with 1 µM 
cyclostreptin or DMSO, and their cytoskeletons were isolated and digested with 
trypsin. The digestion mixture was analyzed by HPLC, with detection by MRM scan 
mode for the m/z of the cyclostreptin-labeled form of 
LTTPTYGDLNHLVSATMSGVTTCLR (not shown). A peak at the expected retention 
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time for the labeled peptide was detected, indicating formation of the adduct in living 
cells. 
To determine the proportion of cellular tubulin that had reacted with 
cyclostreptin, tubulin from cyclostreptin-treated (24 h) and from control A549 cells 
was purified using a one-step ion-exchange procedure. The method yields tubulin of 
> 90% purity (Supplementary Fig. 3a) suitable for MS procedures. Following 
treatment with trypsin, the reaction mixture was subjected to HPLC with analysis in 
the MRM scan mode with Q1 scanning for the m/z of unmodified and cyclostreptin-
linked LTTPTYGDLNHLVSATMSGVTTCLR (Peak 2) and Q3 scanning for a common 
peptide in the y fragmentation series of both labeled and non-labeled peptide (Fig. 
3d). While tubulin from control cells (black filled chromatogram) showed only one 
peak with a m/z of 884.4, which corresponded to triply-charged unmodified peptide, 
tubulin from cyclostreptin-treated cells showed two peaks. The major peak, with m/z 
of 1017.6, corresponded to the triply-charged peptide crosslinked to cyclostreptin, 
and the minor peak was identical with the unmodified peptide from control cells. The 
areas of the peaks derived from tubulin from control and from cyclostreptin-treated 
cells indicated that about 60% of the tubulin from treated cells contained the adduct. 
About 60% of tubulin in paclitaxel-treated 1A9 cells forms polymer18, not very 
different from the proportion of tubulin that reacts with cyclostreptin in A549 cells. 
This suggested near total formation of cyclostreptin adduct in the microtubules of 
treated A549 cells. 
Both Thr220 and Asn228 were covalently modified in the tubulin from 
cyclostreptin-treated cells. The isolated tubulin was digested with chymotrypsin, and 
the digest was subjected to HPLC, with analysis in the MRM mode with Q1 scanning 
for signals at m/z 636.8, 816.4 and 779.4 (corresponding to Peaks 4, 5 (both 
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containing the Thr220 modification) and 6 (containing the Asn228 modification)) and 
Q3 scanning for the 249.0 signal, diagnostic for the covalent reaction with 
cyclostreptin (Supplementary Fig. 3b). The HPLC trace showed the presence of the 
three peaks, confirming that reactions had occurred with both amino acids. 
 
The strained olefin of cyclostreptin is essential for its activity. The chemical 
structure of cyclostreptin (Fig. 1a) is characterized by a highly strained olefin (C2-
C17). C17 and the lactone carbonyl C1 have been proposed as electrophilic sites 
that could react covalently with proteins19. 
In principle, cyclostreptin could undergo nucleophilic attack at either of these 
carbons (Scheme 1), resulting in an increase in mass of the peptide exactly 
coincident with the mass of cyclostreptin. Either an acylation reaction of the lactone 
through nucleophilic attack on C1 (Scheme 1a) or a simple addition of nucleophile to 
C17, with concomitant release of strain due to the C2-C17 bridgehead alkene, are 
reasonable modes of covalent bond formation (Scheme 1b top). A third possibility is 
an addition-elimination sequence of the nucleophile at the C2-C17 bond. This would 
result in the formation of a 9-membered ring alcohol (Scheme 1b bottom). 
Modification of other reactive groups of cyclostreptin, with the exception of the 
unstrained C10-C11 olefin bond, would imply the loss of a water molecule. 
An extensive study of the reactivity of the strained olefin of cyclostreptin with 
model nucleophiles20 led to the conclusion that the reaction is a simple addition of the 
nucleophile to C17 driven by strain release. Generally, the reaction was quantitative, 
as determined by NMR analysis of reaction mixtures, and no evidence for a 9-
member ring product was found. Both Thr and Asn of the peptide have nucleophilic 
side chains that might attack cyclostreptin at C17 by an analogous addition reaction. 
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In order to confirm that the reaction site is the C2-C17 olefin, two cyclostreptin 
analogues were prepared. First, the double bond was epoxidized (Fig. 1a), yielding 
an inactive compound21 (Flutax-2 binding unaltered; no activity against cultured cells 
(Table 2)). Second, the C2-C17 olefin bond was reduced (Fig. 1a), again eliminating 
biological activities of cyclostreptin (no effect on cell proliferation (Table 2) or Flutax-2 
binding; no covalent adduct formed with microtubules as determined by MS). While 
the epoxide is potentially electrophilic at C1, C2 and C17, reduced cyclostreptin no 
longer has the strained olefin, with only C1 being a potential electrophile. However, 
the inactivity of these two analogues buttresses the conclusion that it is the strained 
olefin of cyclostreptin that reacts with tubulin through a simple addition at C17, as 
previously demonstrated with model nucleophiles20. 
 
Molecular modeling. The complex of cyclostreptin with Thr220 was modeled in 
silico by forming a covalent bond with its side chain oxygen (Supplementary Fig. 4). 
The resulting adduct was optimized with MacroModel, identifying a possible binding 
site formed by residues 217-223 and 277-279 from β-tubulin, 323-328 from the 
adjacent α-tubulin, 95-99 from β-tubulin of a neighboring protofilament, and 128-132 
from α-tubulin of a neighboring protofilament (Supplementary Fig. 5). Assuming this 
complex represents that observed experimentally, there are two additional hydrogen 
bonding interactions that would help stabilize the complex: the hydroxyl group at C15 
with Arg278 and the C1 carbonyl group with Thr221. This adduct is further stabilized 
by hydrophobic contacts with a non-polar region of the adjacent α-tubulin (Gln128-
Leu132).  
Cyclostreptin also reacts with with Asn228. The atoms of the backbone of this 
amino acid are located at the lumenal taxoid site, while the side chain forms two 
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strong hydrogen bonds with the exchangeable nucleotide. Therefore, either the 
position of the Asn228 sidechain in microtubules differs from its position in Zn-
induced sheets7,8, or cyclostreptin causes the displacement of the Asn228 side chain 
by forming a non-covalent pre-complex at the paclitaxel site, facilitating a subsequent 
reaction of cyclostreptin with the Asn228 side chain amide. 
 
DISCUSSION 
Cyclostreptin contains two electrophilic functional groups: a strained 
bridgehead olefin and a lactone carbonyl group. Other natural products containing 
such moieties react covalently with nucleophilic residues in protein active sites, 
causing biological effects22,23. 
The biological activities of cyclostreptin overwhelmingly favor microtubules as 
the target of the compound. However, it is not a classical taxoid site ligand. Despite 
strongly displacing taxoid site ligands from microtubules, it only weakly induces 
microtubule assembly5,6,13. 
Our results showed that cyclostreptin is the first MSA that binds covalently to 
microtubules and the first taxoid site ligand whose binding to dimeric tubulin has 
been detected. MS analysis showed that in microtubules cyclostreptin formed a 
covalent bond with either Thr220 or Asn228. In unpolymerized tubulin, only Thr220 
formed a bond with cyclostreptin, and this covalent interaction was much less 
extensive than the reaction with microtubules.  We also demonstrated that both 
crosslinks to β-tubulin form in cyclostreptin-treated cells. Covalent bond formation 
explains the unusual biochemical properties of cyclostreptin, such as the distinct 
requirement for higher temperatures for assembly induction and binding to polymer 
and the high stability of cyclostreptin polymer to disassembly at 0 °C6. Once 
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covalently bound to microtubules, cyclostreptin cannot dissociate, and the 
microtubules cannot disassemble, being more stable than untreated control and 
paclitaxel-induced microtubules.  
Similarly, PtK2 cellular microtubule bundles induced by cyclostreptin were 
more stable than those induced by paclitaxel. Although cyclostreptin is 1/40-th as 
cytotoxic as paclitaxel, it retains its activity in cells resistant to paclitaxel by 
overexpression of P-gp or expression of mutant β-tubulins, becoming more potent 
than paclitaxel in the former case. Therefore, formation of a covalent tubulin adduct 
can be a mechanism to escape these mechanisms of resistance, at least in cultured 
cells. While agents that react covalently with specific targets can be too toxic for use 
in human patients24, some covalently reactive compounds are successfully used 
clinically. Examples are the antiobesity drug tetrahydrolipstatin, which reacts with 
pancreatic lipase25, and the anticancer platinum agents, which react with DNA26. In 
the MDR A2780/AD cells, the covalent adduct of cyclostreptin with tubulin could 
escape the pump. With the tubulin mutants, cyclostreptin affinity for the altered 
tubulin(s) might be modified. Alternatively, the longer time frame involved in cell 
culture studies could still lead to irreversible tubulin inactivation by covalent bond 
formation, even if the tubulin(s) have reduced affinity for cyclostreptin. In summary, 
since the formation of the adduct is a kinetically controlled, irreversible process, 
resistant tumor cells can not escape the effect of cyclostreptin by reduction of affinity 
for the target or enhancing drug efflux, which suggests that the design of ligands that 
covalently react with the taxoid site or other targets might be an effective way to 
address drug resistance. 
The discovery of the covalent reactions of cyclostreptin with tubulin and 
microtubules provides new insights into two obscure aspects of the mechanism of 
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binding of ligands to the taxoid site. First, modeling of paclitaxel-stabilized zinc sheet 
protofilaments into a microtubule structure led to the conclusion that the taxoid site 
was on β-tubulin adjacent to the microtubule lumen7,8. In contrast, kinetic 
measurements, effects of MAPs and antibody binding10,11,15 indicated an easily 
accessible site, most logically on the outer microtubule surface. To reconcile these 
observations, we proposed an exterior taxoid binding site where ligands bound 
initially, prior to transfer to the lumenal site10. The two sites could not be occupied 
simultaneously because of the observed 1:1 binding stoichiometryb. The proposed 
site was at pore type I, including β-tubulin residues Phe214, Thr220, Thr221 and 
Pro222 in the H6-H7 loop10. We have now shown that the taxoid site agent 
cyclostreptin reacts covalently with Thr220 at the proposed pore type I site and with 
Asn228, a residue at the lumenal site. 
The proposed two-step mechanism is consistent with the two-step kinetics of 
binding of fluorescent taxoids to microtubules15. Step one is a bimolecular reaction 
with a micromolar Kd and a kf about 106 M-1 s-1, most consistent with a diffusion 
limited reaction involving an exposed site on the microtubule surface, such as the 
pore type I site containing Thr220. Step two would be a monomolecular reaction with 
a Keq ≈ 20, which indicates that about 5% of the bound ligand would remain at the 
external site. The data obtained with the fluorescent taxoids indicated the first step 
involves binding of the taxoid moiety without immobilization of the fluorescein group, 
since there was no increase in fluorescence anisotropy. This is consistent with the 
taxoid moiety binding at Thr220, and, with longer linkers, the fluorescein moiety was 
fully accessible to antibodies11.  
The hypothesis that binding at the pore type I site, as manifested by the 
reaction of cyclostreptin with Thr220, precedes binding of taxoid site agents to the 
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lumenal site is supported by the fact that covalent binding of cyclostreptin to 
microtubules abolished subsequent binding of every taxoid site agent examined 
(Table I; Fig. 1c). In the Flutax-2  experiment, 50 nM taxoid was incubated with up to 
1 µM taxoid sites preincubated with cyclostreptin, and Flutax-2 binding was 
completely abolished. Even if 1% of the taxoid sites had been accessible to Flutax-2, 
a change of in the fluorescence anisotropy signal would have been detectable. 
Cyclostreptin reacts with tubulin in microtubules in a 1:1 proportion, and thus such 
microtubules, as the MS data show, would have αβ-dimers with the β-tubulin 
modified at both Thr220 and Asn228. While dimers modified at Asn228 would not 
have bound Flutax-2 because the taxoid site was at least partially occupied by the 
cyclostreptin moiety, one can imagine other routes to the lumenal taxoid site when 
the dimers were modified at Thr220. For example, Flutax-2 could have reached the 
lumen through type II pores or through microtubule ends. The failure to detect even 
low levels of Flutax-2 binding argues that an initial interaction at the pore type I site is 
an obligatory route to the lumenal site. 
Second, previous studies12,27 showed that paclitaxel binds avidly to 
microtubules but not to αβ-heterodimers. However, paclitaxel and other taxoid site 
agents will initiate assembly in tubulin solutions in which no microtubules (i.e., 
presumptive binding sites) exist.  It was proposed that paclitaxel might bind to tubulin 
oligomers28, leading to assembly under otherwise unfavorable conditions. In the 
present work, we find a low level of cyclostreptin covalent reactivity with Thr220 in 
dimeric and oligomeric tubulin, under conditions in which microtubule assembly is 
prevented by keeping the free Mg+2 concentration lower than that required to 
assemble microtubules with 20 µM tubulin12. This demonstrates a MSA binding site in 
non-assembled tubulin. No reaction with Asn228 was observed, indicating the 
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lumenal site is not present without microtubule formation. The binding affinity of 
MSAs for the site containing Thr220 in αβ-heterodimers/oligomers must be very low, 
but binding to this site could initiate an assembly reaction, with creation of the higher 
affinity lumenal site and stabilization of nascent polymer. The irreversible covalent 
reaction of cyclostreptin with Thr220 allowed trapping of the binding complex and 
detection of this evanescent species.  
The assembly process could involve transformation of some elements from 
being components of the external site into becoming part of the lumenal site. 
However, the Thr220 cyclostreptin adduct forms under all reaction conditions 
examined, including in preformed, paclitaxel-stabilized microtubules following 
paclitaxel displacement by cyclostreptin. Thus, the external pore type I site must also 
exist to some extent after assembly. Overall, the data presented here demonstrate 
the existence of an MSA binding site in unassembled tubulin and support the 
hypothesis that taxoids reach the lumenal site through transient binding to the pore 
type I site. 
 
METHODS 
Previously described methodologies. Previous papers provide details for 
preparation of tubulin29, cyclostreptin20, epoxidized cyclostreptin21, glutaraldehyde-
stabilized microtubules and quantitation of their taxoid sites10,14, electron microscopy, 
[3H]paclitaxel binding studies6, cytotoxicity assays and cell cycle analysis5 and culture 
and immunofluorescence analysis of PtK2 potoroo kidney cells30. Human ovarian 
carcinoma 1A9, PTX10, PTX2218 and lung carcinoma A549 were cultured as 
described5; A2780 and A2780/AD (P-gp overexpressing) cells were grown in the 
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same medium supplemented with 0.25 units ml-1 of bovine insulin.  Binding of 
[3H]discodermolide and [14C]epothilone B was measured as was [3H]paclitaxel. 
 
Ligands. See Supplementary Methods for preparation of reduced cyclostreptin 
and information about other ligands.  
 
Binding of cyclostreptin to microtubules. Samples containing crosslinked 
microtubules (35 µM taxoid sites) and 30 µM cyclostreptin were incubated for 30 min 
at 25 °C in 3.4 M glycerol, 10 mM NaPi, 1 mM EGTA and 6 mM MgCl2, pH 6.7 (GAB), 
plus 0.1 mM GTP. Samples were processed and extracted, with each organic extract 
residue dissolved in 200 µl of CH3OH14. For uncrosslinked microtubules, samples 
were prepared using 20 µM tubulin plus 25 µM cyclostreptin in GAB, 1 mM GTP. 
Ligands reversibly bound to pelleted polymer or in the supernatant were 
detected by HPLC-MS (Supplementary Methods).  
 
Inhibition of binding of Flutax-2 to microtubules. Crosslinked microtubules (60 
µM) were incubated with 66 µM cyclostreptin, epoxidized cyclostreptin or reduced 
cyclostreptin or DMSO overnight at 22 °C in GAB, 0.1 mM GTP and dialyzed for 5 h 
against the same solution. Flutax-2 (50 nM) was titrated with these preparations, and 
Ka’s for Flutax-2 binding were calculated14.  
Competition of cyclostreptin with Flutax-2 was also performed with native PtK2 
cytoskeletons stained 10 min with 0.2 µM Flutax-2, washed (8x) in two wells with 2 ml 
of 10 mM Pipes, 1 mM EGTA, 1 mM MgCl2, 4% polyethyleneglycol, pH 6.8 and 
incubated 15 min with 100 µM cyclostreptin or paclitaxel or DMSO. After washing 
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again, coverslips were mounted and examined. Cytoskeletons were also 
preincubated with 10 µM cyclostreptin or paclitaxel or DMSO for 10 min, washed, 
stained with 0.2 µM Flutax-2 and visualized. 
 
Flutax-2 dissociation kinetics. The dissociation kinetics of Flutax-2 from 
microtubules was measured by fluorescence anisotropy (Supplementary Methods). 
 
Purification of tubulin from cells. Five 175 cm2 flasks with a monolayer of A549 
cells were incubated for 24 h with 1 µM cyclostreptin or DMSO. Cells were removed 
with PBS, 0.5 mM EDTA, washed with PBS and harvested by centrifugation.  The cell 
pellet (1 ml) was resuspended in 1 ml of 10 mM NaPi, 1 mM MgCl2, 0.1 mM GTP, 
0.24 M sucrose, pH 7.0 and stored in liquid nitrogen. After thawing the cells, DTT and 
GTP to 1 mM were added, and the cells were hand-homogenized in glass. The 
homogenate was centrifuged (38,000 rpm, 1 h, 4 °C, TLA 100.4 rotor in an Optima 
TLX ultracentrifuge). The supernatant was adjusted to 0.4 M KCl and loaded onto a 
High-Trap DEAE Fast Flow 1 ml column in a FPLC system (GE Healthcare) 
developed at 1 ml min-1. Unbound protein was removed with 5 ml of 10 mM NaPi, 1 
mM MgCl2, 0.1 mM GTP, 0.4 M KCl, pH 7.0. Bound protein was eluted with 0.8 M 
KCl in the same buffer and desalted into 10 mM NaPi, 1 mM MgCl2, 0.1 mM GTP, pH 
7.0 with a Hitrap Desalting column. The tubulin was 90% pure, as determined by 
SDS-PAGE. The tubulin was stored in liquid nitrogen, following addition of 0.24 M 
sucrose. 
 
Protein digestion and sample preparation for MS analysis. Tubulin control, 
cyclostreptin-treated, and reduced cyclostreptin-treated samples were prepared 
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using native microtubules, polymerized for 30 min at 37 °C in GAB, 1 mM GTP (200 
µl, 20 µM tubulin with 2.5% DMSO or 25 µM drug). In another sample, 20 µM tubulin 
in GAB, 1 mM GTP was assembled with 22 µM paclitaxel for 15 min at 37 °C (>97% 
assembly5) and incubated for another 45 min at 37°C following addition of 50 µM 
cyclostreptin to displace bound paclitaxel. Morphology of polymers was always 
verified to be microtubules. Microtubules were harvested by centrifugation as 
described above. Pellets were washed twice with water and suspended in 200 µl of 
50 mM NH4HCO3, 12 mM EDTA, 0.01% SDS, pH 7.6. Unassembled tubulin samples 
were prepared using 20 µM GTP-tubulin in 10 mM NaPi, 1 mM EDTA, 0.1 mM GTP, 
pH 7.0 without (dimeric tubulin) or with 1.5 mM MgCl2 (oligomeric tubulin) and 2.5% 
DMSO or 25 µM cyclostreptin. Samples were centrifuged as above to remove 
aggregates, 20 µl was diluted 1:1 into 50 mM NH4HCO3 and digested with trypsin (1 
µg sequencing grade, Promega, 2 h, 37 °C) or chymotrypsin (1 µg Type VII, TLCK 
treated, Sigma, 1 h, 25 °C). Reaction mixtures were dried in vacuo and, for analysis, 
dissolved in 5% CH3CN, 0.5% CH3COOH. 
 
Nano-HPLC and tandem triple quadrupole MS analysis of peptides. Peptides 
from control, cyclostreptin-treated and reduced cyclostreptin-treated samples were 
analyzed with a Supelco C18 nano-column, developed with a CH3CN gradient and 
eluted into a Protana nanospray ion-source. Ions were analyzed as described in 
Supplementary Methods. 
 
MRM of selected cyclostreptin-bound peptides derived from unassembled 
tubulin and tubulin isolated from cells. (Supplementary Methods).  
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Detection of cyclostreptin labeling of tubulin by nano-HPLC coupled to three-
dimensional ion-trap MS. Tryptic peptides from control and cyclostreptin-treated 
microtubules were injected onto a Supelco C18 nano-column. A CH3CN gradient was 
used to elute peptides to a PicoTip™ emitter nano-spray needle (New Objective) for 
real-time ionization and peptide fragmentation on an Esquire HCT ion-trap (Bruker 
Daltoniks) mass spectrometer (Supplementary Methods (Supplementary Fig. 6)).  
 
MS data analysis. All chromatograms and MS/MS spectra from the 4000 Q 
Trap system were analyzed with Analyst 1.4.1 (Applied Biosystems). All HPLC-
MS/MS experiments were repeated with five independent samples. Chromatographic 
and MS data from the 3D ion-trap system were processed by DataAnalysis 3.3 
(Bruker Daltoniks). 
 
Molecular modeling of cyclostreptin binding to tubulin. The simulations needed 
to investigate the covalent binding of cyclostreptin were performed with Macromodel 
8.5 over a model of pore type I built from the structure 1JFF in the PDB. 
 
Footnotes 
aWe use the sequence nomenclature of ref. 7. These two residues in β-tubulin are 
actually at positions 218 and 226, respectively31. 
cSimilar stoichiometry has been found for discodermolide (M. Edler, unpublished 
data) and epothilone A and epothilone B binding14. 
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Figure 1. Biochemistry of the cyclostreptin-microtubule interaction. (a) 
Chemical structure of cyclostreptin and analogues. (b) HPLC-MS analysis of 
cyclostreptin extracted from pellets (black) and supernatants (red) after incubation 
with (solid lines) and without (dashed lines) stabilized microtubules. (c) Binding of 
Flutax-2 to stabilized microtubules preincubated with cyclostreptin or DMSO. (d) 
Kinetics of displacement of Flutax-2 from microtubules by cyclostreptin at 2 (black), 5 
(yellow), 10 (magenta), 20 (green) or 40 µM (blue) or 2% DMSO (orange). Left Inset: 
Displacement of Flutax-2 by docetaxel at 2 (black solid line) or 20 µM (red dotted 
line). Right Inset: Dependence of the observed rate constant on [cyclostreptin], solid 
line fit of the data to the kinetic model proposed. 
Figure 2. Inhibition of binding of Flutax-2 to PtK2 cytoskeletons by 
preincubation with cyclostreptin (a-c) and irreversibility of microtubule effects 
on PtK2 cells grown in cyclostreptin (d-i). (a-c) Cytoskeletons were preincubated 
with DMSO and stained with Flutax-2 (a), 10 µM cyclostreptin (b) or 10 µM paclitaxel 
(c). Insets: Mitotic spindles stained with Flutax-2. (d-f) Cells cultured for 7 h in the 
presence of DMSO and immunostained (d), 5 µM cyclostreptin (e) or 10 µM 
paclitaxel (f). (g-i), Cells washed after 7 h and left in culture for 16 h. DMSO 
treatment (g), cyclostreptin treatment (h) and paclitaxel treatment (i). The size bar 
represents 10 µm, and all panels and insets have the same magnification. 
Figure 3. MS analyses of cyclostreptin binding to tubulin. Total ion 
chromatogram of the precursor ion scanning of fragment at m/z 249.0 from control (a) 
or cyclostreptin-treated (b) tubulin samples, digested with trypsin (Try) or 
chymotrypsin (Chy). (c) MRM experiments with unassembled, cyclostreptin-treated 
dimeric tubulin samples. The upper insets show MRM results for the corresponding 
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dimeric tubulin control samples. Black arrows indicate the retention time expected for 
signals from Peaks 2 (left, trypsin) and 5 (right, chymotrypsin). (d) Sequence of the β-
tubulin peptide (residues 219-243) containing the peptides labeled. Black triangles 
indicate the theoretical chymotrypsin cleavage sites within the tryptic peptide. (e) 
MRM experiments with trypsin-digested tubulin extracted from untreated or 
cyclostreptin-treated cells. 
Scheme 1. Possible reaction mechanisms between cyclostreptin and 
nucleophiles. (a) acylation reaction of the lactone through nucleophilic attack at C1. 
(b) Top, simple addition of the nucleophile to C17; bottom, addition-elimination of the 
nucleophile at the C2-C17 bond, with formation of a 9-member ring alcohol.
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TABLE 1 
Dependence on order of ligand addition for the binding of discodermolide, paclitaxel, or 
epothilone B to the taxoid site. 
 
 
Bindinga of 2 µM 
 [3H]Discodermolide [14C]Epothilone B [3H]Paclitaxel 
 A B A B A B 
(20 µM) --------% radioactive compound boundb ± SD -------------- 
Cyclostreptin 96 ± 4 19 ± 6 79 ± 10 12 ± 1 60 ± 2 25 ± 2 
Epothilone A 95 ± 1 96 ± 5 49 ±  1 49 ± 1 46 ± 3 49 ± 1 
Epothilone B 76 ± 1 79 ± 5 9 ± 2 9 ± 1 31 ± 1 33 ± 4 
Discodermolide 27 ± 1 31 ± 10 NDc ND ND ND 
 
 
aA columns: the radiolabeled ligand was added prior to the nonradiolabeled competitor. 
B columns: the nonradiolabeled competitor was added prior to the radiolabeled ligand. 
bThe figures represent the percentage of radiolabeled compound bound in the 
presence of the competitor as compared with the compound bound in its absence. 
cND not determined.
 32
                                                           TABLE 2 
 Effects of cyclostreptin as compared with paclitaxel and docetaxel on the growth of 
human carcinoma cells.  
 
IC50 (nM) ± SDa 
Cell line 





Paclitaxel 1±0.3 900±200(900)b  1.1±0.2 30±9(27) 19±5(17) 3.6±0.4 
Docetaxel 0.5±0.1 285±60 (570) 0.6±0.1 NDc ND 7.2±0.3 
Cyclostreptin 43.5±4 51±12 (1.2) 44±6 240±50(5) 58±7(1.3) 45.5±11 
Epoxidized 
cyclostreptin 
Inactived   Inactive Inactive Inactive Inactive Inactive 
Reduced 
Cyclostrepytin 
Inactive Inactive Inactive Inactive Inactive Inactive 
 
aIC50 values determined in the ovarian carcinoma lines A2780 (parental line), 
A2780/AD (a MDR line overexpressing P-gp), 1A9 (a clone of A2780), and PTX10 and 
PTX22 (paclitaxel-resistant tubulin mutants derived from 1A9) and the non-small lung 
cell carcinoma line A549. IC50 values were obtained in at least four independent 
experiments. bThe numbers in parentheses are the calculated relative resistance 
values, obtained by dividing the IC50 value of the resistant line by the IC50 value of the 
parental line. cND not determined. dInactive, no inhibition at 5 µM. 
 
 
 
 
 
 
 
 
 
 
 
 




